Apogee Therapeutics, Inc. APGE Non Cash Lease Expense
Non Cash Lease Expense at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept apge:NonCashLeaseExpense.
The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Apogee Therapeutics, Inc.'s non cash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Apogee Therapeutics, Inc.'s non cash lease expense?
- Apogee Therapeutics, Inc. (APGE) reported non cash lease expense of $980K in Q1 2026.
- How has Apogee Therapeutics, Inc.'s non cash lease expense changed year-over-year?
- Apogee Therapeutics, Inc.'s non cash lease expense increased by 14.4% year-over-year, from $857K to $980K.
- What is the long-term trend for Apogee Therapeutics, Inc.'s non cash lease expense?
- Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s non cash lease expense has grown at a 550.1% compound annual growth rate (CAGR), from $87K to $3.68M.
- What does non cash lease expense mean?
- This represents the portion of lease expenses recognized in the income statement that does not involve an immediate cash outflow, typically associated with the amortization of right-of-use assets. It is added back to net income in the cash flow statement to reconcile accounting expenses with actual cash payments. This metric helps analysts understand the impact of lease accounting standards on reported profitability without affecting liquidity.